SALT LAKE CITY, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced a positive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) for its investigational drug rivoceranib in combination with camrelizumab as a treatment option for hepatocellular carcinoma (HCC), the most common type of liver cancer and cause of more than 830,000 annual deaths worldwide. The meeting reaffirmed Elevar’s plans to file an NDA for the combination of rivoceranib plus camrelizumab as early as is feasible in 2023. 

Please refer to the following website for further details: https://www.globenewswire.com/news-release/2022/10/11/2532328/0/en/Elevar-Therapeutics-Announces-Positive-Pre-NDA-Meeting-for-Rivoceranib-Combination-With-Camrelizumab-as-Hepatocellular-Carcinoma-Treatment-Option.html